1-3 of 3
Edward Bradley
Close
Sort by
Journal Articles

Durable Responses with the JAK1/ JAK2 Inhibitor, INCB018424, In Patients with Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Refractory or Intolerant to Hydroxyurea (HU)

Srdan Verstovsek, MD, PhD, Francesco Passamonti, Alessandro Rambaldi, MD, Giovanni Barosi, MD, Peter J. Rosen, MD, Richard Levy, Edward Bradley, William Garrett, Kris Vaddi, Nancy Contel, Victor Sandor, Reid Michael Huber, PhD, Lee P. Schacter, MD, PhD, Elisa Rumi, Elisabetta Gattoni, Elisabetta Antonioli, Lisa Pieri, MD, Mario Cazzola, MD, Hagop Kantarjian, MD, Tiziano Barbui, MD, Alessandro M. Vannucchi, MD
Journal: Blood
Blood (2010) 116 (21): 313.
https://doi.org/10.1182/blood.V116.21.313.313
Published: 2010
Journal Articles

INCB018424, a Selective JAK1/2 Inhibitor, Significantly Improves the Compromised Nutritional Status and Frank Cachexia in Patients with Myelofibrosis (MF).

Ruben A. Mesa, MD, FACP, Srdan Verstovsek, Hagop M. Kantarjian, MD, Animesh D. Pardanani, MBBS, PhD, Steven Friedman, MD, Robert Newton, Susan Erickson-Viitanen, Deborah Hunter, John Redman, MD, Swamy Yeleswaram, Edward Bradley, MD, Ayalew Tefferi, MD
Journal: Blood
Blood (2008) 112 (11): 1760.
https://doi.org/10.1182/blood.V112.11.1760.1760
Published: 2008
Journal Articles

The JAK Inhibitor, INCB018424, Demonstrates Durable and Marked Clinical Responses in Primary Myelofibrosis (PMF) and Post-Polycythemia/Essential Thrombocythemia Myelofibrosis (Post PV/ETMF).

Srdan Verstovsek, Hagop M. Kantarjian, MD, Animesh D. Pardanani, MBBS, PhD, Deborah Thomas, MD, Jorge Cortes, MD, Ruben A. Mesa, MD, FACP, William J. Hogan, MBChB, John R. Redman, MD, Sue Erickson-Viitanen, Richard Levy, MD, Kris Vaddi, PhD, DVM, Edward Bradley, MD, Jordan Fridman, PhD, Ayalew Tefferi, MD
Journal: Blood
Blood (2008) 112 (11): 1762.
https://doi.org/10.1182/blood.V112.11.1762.1762
Published: 2008